Catalent to acquire Juniper Pharmaceuticals

5 Jul 2018

$133 million deal adds European Early Development Center of Excellence to global network.

Catalent has agreed to acquire Juniper Pharmaceuticals, including its Nottingham, UK-based Juniper Pharma Services division. When combined with Catalent’s existing industry-leading drug development and manufacturing capabilities in the US and Europe, the acquisition of Juniper will expand and strengthen Catalent’s offerings in formulation development, bioavailability solutions and clinical-scale oral dose manufacturing, and will complement its integrated global clinical and commercial supply network.

Catalent to acquire Juniper Pharmaceuticals
Catalent’s acquisition of Jupiter Pharmaceuticals will complement its own early-phase development centers of excellence, such as the one in San Diego (pictured) where Catalent has extensive experience in spray-drying technologies.

“Juniper’s proven solutions and capabilities will further support Catalent’s strategic goal to be the most comprehensive partner for pharmaceutical innovators,” commented Jonathan Arnold, President of Catalent Oral Drug Delivery. “Juniper’s scientific expertise in early-phase product development and supply will help our customers unlock the full potential of their molecules and provide better treatments to patients, faster.”

Juniper’s nearly 150 employees have deep scientific expertise in formulation development, and supply, and will augment Catalent’s current portfolio of solid-state screening, preformulation, formulation, analytical, and bioavailability enhancement solutions, including development of spray-dried dispersions, with integrated development, analytical, and clinical manufacturing co-located in its Nottingham facility.

Catalent will continue to support Juniper’s CRINONE (progesterone gel) franchise marketed by Merck KGaA outside of the US. Juniper’s Intravaginal Ring development pipeline was previously licensed to Daré Bioscience, and Catalent will not be involved in the further development of this program. The acquisition of Juniper is subject to certain customary closing conditions, including that a majority of Juniper’s shares are tendered into the offer, and is expected to close in the first quarter of Catalent’s 2019 fiscal year, which began on 1 July 2018.

Like Catalent, Juniper has expertise in solid-state and preclinical formulation screening for lead-candidate selection, phase-appropriate dose-form development, and superior technologies for challenging molecules, which will strengthen and expand on Catalent’s OptiForm Solution Suite platform. Juniper provides bioavailability enhancement solutions for the development of poorly soluble compounds, including nano-milling, spray drying, hot-melt extrusion, lipid-based drug delivery, and cGMP clinical manufacturing, including specialized facilities and controls for potent and controlled substances.

In 2016, Catalent purchased Pharmatek Laboratories, Inc. and has invested in its San Diego facility to create a center of excellence for early drug development on the U.S. West Coast. Earlier this year, Catalent announced that it would invest in its Somerset, New Jersey facility to create a similarly focused center of excellence on America’s East Coast. Juniper will now provide similar capabilities in the UK and will complement Catalent’s multi-site oral manufacturing network to provide pharmaceutical innovators with a comprehensive solution to accelerate their drug development processes.

Read More

Related news

TraceLink unveils Product Information Manager for its digital information sharing platform

TraceLink unveils Product Information Manager for its digital information sharing platform

12 Jul 2018

Product Information Manager addresses a broad range of use cases, beginning with saleable returns.

Read more 
Stability studies trends

Stability studies trends

10 Jul 2018

Dr Ramesh Jagadeesan, Sr. Director - Analytical Development at Recipharm, speaks to CPhI Online on the trends and challenges involved with conducting stability studies for firms that supply to multiple countries, and the advantages of using a contracto...

Read more 
Recipharm launches standalone serialisation service

Recipharm launches standalone serialisation service

5 Jul 2018

Company will be able to add 2D codes, human-readable text and tamper evidence to pre-packed medicines using existing equipment across its facilities.

Read more 
CPhI Worldwide opens entries for 15th Annual Pharma Awards

CPhI Worldwide opens entries for 15th Annual Pharma Awards

5 Jul 2018

Winners will be announced live at the Gala Ceremony in Madrid with over 500 of Pharma’s top executives.

Read more 
Insights in lyophilization science

Insights in lyophilization science

4 Jul 2018

The latest developments in process development, nucleation control, scale-up of freeze drying cycles and development in lyophilization technology.

Read more 
Bosch to sell its packaging business

Bosch to sell its packaging business

4 Jul 2018

Packaging technology is not a core Bosch business.

Read more 
Plasticell leads gene therapy manufacturing consortium

Plasticell leads gene therapy manufacturing consortium

3 Jul 2018

Consortium to develop advanced technologies for the manufacturing of ex vivo gene therapies.

Read more 
Forté Pharma strengthens its leadership in weight control in France

Forté Pharma strengthens its leadership in weight control in France

1 Jul 2018

Company consolidated as one of the leading laboratories in weight control thanks to the development of its existing range and new launches.

Read more 
I Holland woos exhibition visitors with new tabletting technologies

I Holland woos exhibition visitors with new tabletting technologies

28 Jun 2018

Company's Wear Indicator Layer attracts the most attention.

Read more 
Ingredients to improve bioprocess manufacturing efficiency

Ingredients to improve bioprocess manufacturing efficiency

27 Jun 2018

Experts warn bio industry needs to do more to create a sustainable pipeline of talent.

Read more